1. Scrip

AZ’s Farxiga CKD Trial Hits All Primary, Secondary Targets

DAPA-CKD Was Stopped Early In March For Efficacy

 
• By Sten Stovall

Study assessed Farxiga’s effect on renal outcomes and CV mortality in chronic kidney disease patients with and without type 2 diabetes.

Dartboard
Study assessed Farxiga’s effect on renal outcomes and CV mortality in chronic kidney disease patients with and without type 2 diabetes. • Source: Shutterstock

AstraZeneca PLC has released topline data showing its sodium glucose cotransporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin) met all its primary and secondary endpoints in a Phase III study of patients with chronic kidney disease (CKD) with and without type2 diabetes.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Genitourinary

More from Therapy Areas

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.